Malin Hosts Capital Markets Day Today
Dublin-Ireland, 8 November 2018: Malin Corporation plc. (ISE:MLC, "Malin"), a company investing in highly innovative life sciences companies, is today hosting a Capital Markets Day for institutional investors and analysts in London.
The Board announced in July 2018 that it would undertake a strategic review of the business and is today presenting the outcome of that review and providing an update on Malin’s vision, strategy, progress and outlook.
Ian Curley, Malin’s Executive Chairman, will host the event with other members of the Malin team including Darragh Lyons, Chief Business and Financial Officer, and Dr Andrew von Eschenbach, Chief Medical Advisor. The team will expand on the actions taken to refocus Malin’s business to create an effective platform for value creation, as well as outlining the new capital allocation strategy which includes a commitment to return capital to shareholders following significant asset realisation events. Malin will target assets focused on oncology, immunology and genetic diseases where the Company believes the most innovative life science and healthcare technologies will deliver transformative outcomes for patients and generate significant shareholder return.
The event will also include presentations on Malin’s four priority assets: Poseida Therapeutics, Kymab, Immunocore and Viamet, the portfolio companies which make up approximately 70% of Malin’s total portfolio fair value (as at 30 June 2018).
Presenters at the Malin Capital Markets Meeting will include:
- Ian Curley, Executive Chairman of Malin Corporation plc
- Darragh Lyons, Chief Business and Financial Officer of Malin Corporation plc
- Andrew von Eschenbach, M.D., Chief Medical Advisor of Malin Corporation plc
- Jean-Michel Cosséry, Ph.D., Director of Malin Corporation plc
- Samuel Cohen, Ph.D., Director, Investments Team of Malin Corporation plc
- Robert J. Schotzinger, M.D., Ph.D., President and Chief Executive Officer of Viamet Group
- Stephen Megit, Ph.D., VP of Business Development of Immunocore Ltd
- Anne Hyland, Chief Financial Officer of Kymab Ltd
The meeting will be held at the London Stock Exchange, 10 Paternoster Row, London, EC4M 7LS. The event will start at 1:30pm GMT with a networking lunch, followed by a series of presentations and Q&A sessions starting promptly from 2:30pm GMT. The day will conclude with an informal drinks and networking session from approximately 5:30pm GMT.
A live webcast of the event will be available on the Malin website at http://www.malinplc.com/. A replay of the event and presentation slides will be made available shortly after.
To dial into the webcast, please use the following details:
UK/International: +44 (0)330 336 9127
Ireland: +353 (0)1 246 5638
US: +1 929 477 0448
Confirmation code: 9421002
Please contact firstname.lastname@example.org if you would like to attend today's event and have not already registered.
No new price sensitive information will be disclosed.
For further information, please contact:
Jessica Bergin, Director of Investor Relations and External Reporting
Tel: +353 (0)1 901 5700
Powerscourt (Ireland PR) Consilium Strategic Communications (UK PR)
Eavan Gannon Mary-Jane Elliott / Jonathan Birt
Tel: +353 87 236 5973 Tel: +44 (0)20 3709 5700
Davy Corporate Finance (ESM Adviser)
Brian Garrahy / Daragh O’Reilly
Tel: +353 1 679 6363
About Malin Corporation plc
Malin (ISE:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on Euronext Dublin. For more information visit www.malinplc.com